Categories: News

CO2 GRO Inc. Announces a Commercial Feasibility in South Africa with Marketing Partner PharmaCrop Pty for Mountain View’s Outdoor Macadamia Nursery

TORONTO, ON / ACCESSWIRE / March 22, 2021 / Toronto based CO2 GRO Inc. (“GROW”) (TSXV:GROW)(OTCQB:BLONF)(Frankfurt:4021) is pleased to announce a commercial feasibility of a CO2 Delivery Solutions™ system with South Africa based macadamia nursery grower, Mountainview Nursery (“Mountain View“). This outdoor feasibility project was sourced by GROW’s South Africa based Marketing Partner PharmaCrop Pty (“PharmaCrop“).

The commercial feasibility will be conducted in a section of Mountain View’s macadamia tree seedling nursery utilizing a custom-built support structure for hanging misters and piping. The primary focus of the commercial feasibility is to assess CO2 Delivery Solutions’™ effects on accelerating the growth of macadamia tree seedlings in the nursery.

Mountain View’s CFO, Ruan Van Der Westerhuisen stated, “We are excited to start the use of CO2 GRO’s technology in partnership with PharmaCrop, which will enable us to enhance root development and produce macadamia trees for transplanting in a shorter time.”

PharmaCrop’s Principal, Jason Field commented, “South Africa’s high value macadamia market is expanding rapidly and is one of the target markets to sell CO2 Delivery Solutions™ systems. Macadamia trees produce high value nuts and are expensive to grow and maintain. Reducing the time to transplant nursery trees to the mature section can dramatically increase the value of a macadamia farm, which can take up to 7 years before realizing returns.”

GROW’s VP Sales & Strategic Alliances, Aaron Archibald stated “Our recent partnership with PharmaCrop has led to this first open air outdoor commercial feasibility in South Africa. High value crops grown in open air farms are a much larger market than greenhouses that PharmaCrop is pursuing throughout South Africa. A successful commercial feasibility at the Mountain Views facility could open not only a new market in South Africa but also globally”.

About Mountain View

Mountain View Nursery is located in the Lowveld, Mpumalanga area of South Africa. It is dedicated to growing quality Macadamia tree seedlings for South African growers. Mountain View Nursery is a proud member of The South African Macadamia Association (SAMAC) and the thirteen-member Seedling Growers Association of South Africa (SGASA).

About CO2 GRO Inc.

GROW’s proprietary CO2 Delivery Solutions™ technology is poised to revolutionize the global high value plant greenhouse industry. Its usage provides growers the opportunity to increase revenue by up to 30% and suppress the development of pathogens thereby reducing crop loss risks in an environmentally friendly and sustainable manner.

CO2 Delivery Solutions™ dissolves and saturates CO2 gas into water creating a bubble-less aqueous CO2 solution. When the solution is misted onto high value plants it increases revenue to greenhouse growers by up to 30% through a combination of larger plants and shorter crop grow time.

The worldwide markets for GROW’s disruptive CO2 Delivery Solutions™ technology are the 50 billion square feet of greenhouses, 85% of which cannot economically or optimally employ CO2 gas to maximize revenue and the 600 billion square feet of open air protected ag, 100% of which cannot employ CO2 gas. GROW’s CO2 Delivery Solutions™ technology now enables all greenhouse growers everywhere to maximize revenue easily with low systems capital costs and ease of systems installation into overhead misting systems.

GROW’s management is moving quickly to capitalize on this world-wide opportunity by establishing marketing partner relationships internationally. Currently marketing partnerships are in place covering 14 countries with quickly growing interest from multiple other potential partners. In North America, GROW maintains regional sales representatives and support teams. GROW’s CO2 Delivery Solutions™ is protected by a suite of patents and patent pending applications.

GROW’s high value plant data developed through scientific research and commercial feasibilities with multiple potential customers has demonstrated the beneficial effects of CO2 Delivery Solutions™ technology on many high value plants including peppers, lettuce, strawberries, microgreens, kale, medicinal plants, cannabis, hemp, roses and orchids.

GROW’s CO2 Delivery Solutions™ technology is environmentally friendly, sustainable, provides for crops grown to be certified as organic and supports locally grown food minimizing the risk associated with extended global food chains.

Our organization is committed to fostering and maintaining an inclusive respectful environment providing equal opportunities at all levels to people of different genders, nationalities, and age and education background with a focus on values that align with our corporate culture.

GROW is conscious of the environment, our impact on it and also for the health and welfare of our staff, our clients, partners and stakeholders. We support the best practices for the COVID-19 pandemic and have revisited our previous procedures for sales and business development. Further, GROW’s CO2 Delivery Solutions™ technology does not pose any health and safety risks to employees.

As a global organization, GROW is committed to good Environment, Social and Governance practices and we do so wherever possible to ensure we are an employer of choice and opportunity. Our mission is to accelerate the growth of all value plants safely, economically and naturally using our patented advanced CO2 Delivery Solutions™.

We do well for the planet, the people we work with who benefit from our solutions and create profits for our shareholders, clients, partners and value in the long term.

Forward-Looking Statements

This press release contains statements which constitute “forwardlooking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: statements regarding the future direction of the Company; the ability of the Company to successfully achieve its business and financial objectives; plans for expansion and the ability of the Company to obtain, develop and foster its business relationships; and expectations for other economic, business, and/or competitive factors. Investors are cautioned that forwardlooking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates that management considered reasonable at the date the statements are made. Such assumptions include but are not limited to: general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and that good relationships with business partners will be maintained. Although the Company believes that the expectations reflected in such forwardlooking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forwardlooking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; in particular, in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; the biotechnology industry and the greenhouse growers market are highly competitive, and technical advances in the industry will impact the success of the Company, and other risks described in the Company’s filings that are available at www.sedar.com. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forwardlooking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forwardlooking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please visit www.co2gro.ca or contact Michael O’Connor, Investor Relations Manager at 604-317-6197 or michael.oconnor@co2gro.ca

SOURCE: CO2 Gro Inc.

View source version on accesswire.com:
https://www.accesswire.com/636728/CO2-GRO-Inc-Announces-a-Commercial-Feasibility-in-South-Africa-with-Marketing-Partner-PharmaCrop-Pty-for-Mountain-Views-Outdoor-Macadamia-Nursery

Staff

Recent Posts

BioHarvest Launches VINIA SuperFood Functional Tea Line

Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood…

44 minutes ago

Neurotech Innovator UNEEG Medical Receives FDA Breakthrough Device Designation Within Monitoring and Diagnostic of Epilepsy

The designation is a result of UNEEG's strong focus on developing novel disease management support…

44 minutes ago

Lexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC /…

44 minutes ago

S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization

CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio…

44 minutes ago

Acreage Provides Update on Corporate Transactions

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Acreage Holdings, Inc. ("Acreage" or…

44 minutes ago